What is the price target for AFIB stock?
6 analysts have analysed AFIB and the average price target is 1.53 USD. This implies a price increase of 1600% is expected in the next year compared to the current price of 0.09.
ACUTUS MEDICAL INC (AFIB) Forecast, Price Target & Analyst Ratings
NASDAQ:AFIB • US0051111096
Current stock price
0.09 USD
-0.03 (-26.83%)
At close:
0.06 USD
-0.03 (-33.33%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ACUTUS MEDICAL INC (AFIB).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Aug 5, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$0.45
- Revenue Estimate
- 7.782M
Price Target Details & History
Consensus Price Target and Range
Mean target
$1.53
Upside
+ 1,600.00%
From current price of $0.09 to mean target of $1.53, Based on 6 analyst forecasts
Low
$0.51
Median
$1.53
High
$2.63
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
6 Wall Street analysts provided a forecast for the next 12 months for AFIB. The average price target is 1.53 USD. This implies a price increase of 1600% is expected in the next year compared to the current price of 0.09.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
AFIB was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about AFIB.
In the previous month the buy percentage consensus was at a similar level.
AFIB was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-08-16 | Goldman Sachs | Maintains | Neutral |
| 2022-06-24 | BTIG | Maintains | Buy |
| 2022-04-27 | BTIG | Upgrade | Neutral -> Buy |
| 2022-04-14 | Goldman Sachs | Maintains | Neutral |
| 2022-01-20 | BTIG | Downgrade | Buy -> Neutral |
| 2022-01-14 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2021-11-12 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-11-12 | Canaccord Genuity | Maintains | Buy |
| 2021-10-22 | Goldman Sachs | Initiate | Neutral |
| 2021-07-15 | Canaccord Genuity | Upgrade | Hold -> Buy |
| 2021-03-19 | William Blair | Downgrade | Outperform -> Market Perform |
| 2021-03-19 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-03-19 | Canaccord Genuity | Maintains | Hold |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Aug 5, 2024
- Period
- Q2 / 2024
- EPS Estimate
- -$0.45
- Revenue Estimate
- 7.782M
- Revenue Q2Q
- 47.14%
- EPS Q2Q
- 29.30%
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
AFIB is expected to report earnings on 8/5/2024. The consensus EPS estimate for the next earnings is -0.45 USD and the consensus revenue estimate is 7.78M USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates 2024 - 2030
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 17.26M 104.02% | 16.36M -5.21% | 7.164M -56.21% | 32.489M 353.50% | 50.445M 55.27% | 100.81M 99.84% | 165.79M 64.46% | 180.23M 8.71% | 207.47M 15.11% | 234.7M 13.12% | |
| EBITDA YoY % growth | -105.73M -20.00% | -85.93M 18.73% | -20.617M 76.01% | -55.692M -170.13% | -46.818M 15.93% | -23.154M 50.54% | 3.264M 114.10% | 35.216M 978.92% | 60.741M 72.48% | 76.067M 25.23% | |
| EBIT YoY % growth | -112.12M -22.76% | -92.41M 17.58% | -20.808M 77.48% | -63.597M -205.64% | -55.743M 12.35% | -37.128M 33.39% | -13.566M 63.46% | 7.676M 156.58% | 33.201M 332.53% | 48.527M 46.16% | |
| Operating Margin | -649.59% | -564.85% | -290.45% | -195.75% | -110.50% | -36.83% | -8.18% | 4.26% | 16.00% | 20.68% | |
| EPS YoY % growth | -4.12 75.43% | -2.69 34.71% | N/A 12.16% | -1.81 23.31% | -1.43 21.20% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.45 29.30% | -0.44 1.78% | -0.44 19.37% |
| Revenue Q2Q % growth | 7.782M 47.14% | 8.418M 60.71% | 9.689M 35.25% |
| EBITDA Q2Q % growth | -14.076M 13.16% | -13.617M -14.08% | -13.719M 33.46% |
| EBIT Q2Q % growth | -16.065M 14.46% | -15.555M 0.19% | -15.708M 24.51% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
13.68%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
46.08%
Revenue Next 5 Year
59.26%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
18.78%
EBIT Next 5 Year
20.05%
ACUTUS MEDICAL INC / AFIB Forecast FAQ
Can you provide the upcoming earnings date for ACUTUS MEDICAL INC?
ACUTUS MEDICAL INC (AFIB) will report earnings on 2024-08-05, after the market close.
Can you provide the consensus estimates for ACUTUS MEDICAL INC next earnings?
The consensus EPS estimate for the next earnings of ACUTUS MEDICAL INC (AFIB) is -0.45 USD and the consensus revenue estimate is 7.78M USD.
Can you provide the expected long term growth rate for ACUTUS MEDICAL INC stock?
The expected long term growth rate for ACUTUS MEDICAL INC (AFIB) is 46.08%.